Zoetis
ZTS
$71.33
-0.10%
Zoetis is the world's largest animal health company, selling anti-infectives, vaccines, parasiticides, diagnostics, and other health products for both companion animals (dogs, cats, horses) and production animals (cattle, swine, poultry, fish), with roughly 65% of revenue derived from companion animals and 35% from livestock. Spun out of Pfizer in 2013, the company has built a distinct competitive identity as the scale leader in a consolidated, innovation-driven industry, underpinned by a durable portfolio of parasiticides, dermatology treatments, and vaccines that generate recurring, annuity-like revenue streams. The current investor narrative has turned sharply negative: after a long run as a premium-compounding healthcare name, the stock has de-rated violently as analysts publicly question Zoetis' pathway to growth amid sliding key segments, with the shares down more than 50% over the past year and the market now debating whether this is a cyclical air pocket or a structural slowdown in companion-animal spending. With the stock trading near its 52-week low and sell-side price targets still well above the market price, the central debate is whether the company's innovation pipeline and international expansion can reaccelerate growth or whether competitive and macro pressures will persist.…
ZTS
Zoetis
$71.33
Related headlines
Investment Opinion: Should I buy ZTS Today?
The synthesized recommendation is Hold. The core thesis is that Zoetis is a high-quality market leader trading at a deep discount due to cyclical growth concerns, but the lack of near-term catalysts and deteriorating momentum warrant a cautious stance. The analyst consensus rating is Buy (mean 2.22), with an average target price of $96.00, implying 34.5% upside, but the stock's 51.5% one-year decline and 1.89% revenue growth suggest the market is pricing in a structural slowdown. Supporting evidence includes a forward PE of 10.93x, which is well below the trailing PE of 20.87x and the broader healthcare sector average, a gross margin of 70.5% that demonstrates pricing power, and $2.14 billion in trailing free cash flow. However, the debt-to-equity ratio of 2.85 and the price-to-book ratio of 16.75 are red flags. The biggest risks are a continued decline in companion-animal spending, competitive pressures, and a potential earnings miss that could trigger further downside. The rating would upgrade to Buy if revenue growth reaccelerates above 5% or if the stock breaks above $80 with strong volume, and downgrade to Sell if it breaks below $71 on high volume or if forward EPS estimates are revised downward. Relative to its history and peers, the stock appears undervalued on a forward earnings basis but overvalued on book value and sales multiples.
Sign up to view all
ZTS 12-Month Price Forecast
The forward-looking view is neutral with medium confidence. The stock is deeply oversold and trades at a significant discount to analyst targets, but the deceleration in revenue growth to 1.89% and the 51.5% one-year decline suggest that the market is pricing in a structural slowdown. The bull case hinges on a cyclical rebound in companion-animal spending, while the bear case assumes continued competitive pressures. I would upgrade to bullish if revenue growth accelerates above 5% or if the stock breaks above $80 with strong volume, and downgrade to bearish if it breaks below $71 on high volume or if forward EPS estimates are revised downward.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Zoetis's 12-month outlook, with a consensus price target around $96.00 and implied upside of +34.6% versus the current price.
Average Target
$96.00
0 analysts
Implied Upside
+34.6%
vs. current price
Analyst Count
—
covering this stock
Price Range
$80 - $155
Analyst target range
Bulls vs Bears: ZTS Investment Factors
The bear case currently has stronger evidence: the stock is down 51.5% in a year, revenue growth has decelerated to 1.89%, and analysts are openly questioning the growth trajectory. However, the bull case rests on deep value — a forward PE of 10.93x, a 34.5% upside to the average analyst target of $96, and a 70.5% gross margin that underscores the company's competitive moat. The single most important tension is whether the companion-animal spending slowdown is cyclical or structural; if it's cyclical, the stock is dramatically oversold, but if structural, further downside is likely. The market is pricing in a severe earnings decline, creating a high-risk, high-reward setup.
Bullish
- Deep Value After 51% Collapse: ZTS trades at $71.40, down 51.5% over the past year and just 0.6% above its 52-week low of $71.00. The forward PE of 10.93x is less than half the trailing PE of 20.87x, implying the market expects EPS to nearly double next year, while the PEG ratio of 2.04 still reflects growth concerns.
- Analyst Targets Imply 34% Upside: All 15 covering analysts rate the stock a Buy (recommendation mean 2.22), with an average target price of $96.00 — 34.5% above the current $71.40. The low target of $80.00 still offers 12% upside, and the high target of $155.00 implies 117% upside, suggesting sell-side sees significant mispricing.
- Fortress Margins and Cash Generation: Gross margin stands at 70.5% and operating margin at 38.0%, while net margin is 28.2%. The company generated $2.14 billion in trailing free cash flow, and its current ratio of 3.03 indicates ample liquidity to fund operations and dividends.
- Low Beta Defensive Profile: With a beta of 0.729, ZTS is significantly less volatile than the broader market. This defensive characteristic, combined with a 1.59% dividend yield and a conservative 33.3% payout ratio, makes it attractive for risk-averse investors seeking healthcare exposure.
Bearish
- Catastrophic Price Collapse: The stock has fallen 51.5% over one year, 38.3% over six months, and 43.3% year-to-date, with a max drawdown of -54.45%. This severe underperformance relative to the S&P 500 (which gained 15.0% over one year) signals deep structural concerns rather than a temporary dip.
- Growth Has Stalled: Q1 2026 revenue grew only 1.89% year-over-year, a sharp deceleration from historical double-digit growth. Analysts are publicly questioning the company's pathway to growth as key segments slide, and the forward PE of 10.93x suggests the market expects earnings to decline or stagnate.
- Extreme Leverage and Valuation Disconnect: Debt-to-equity stands at 2.85, and the price-to-book ratio is 16.75 — extraordinarily high for a company with slowing growth. The EV/EBITDA of 15.48 and PS ratio of 5.89 indicate the stock is not cheap on absolute terms despite the price decline.
- Earnings Quality Concerns: Trailing EPS is just $0.048, making the trailing PE of 20.87x misleadingly low. The forward PE of 10.93x relies on analyst EPS estimates of $9.06, which may be overly optimistic given the 1.89% revenue growth and competitive pressures.
ZTS Technical Analysis
Beta
0.73
0.73x market volatility
Max Drawdown
-54.5%
Largest decline past year
52-Week Range
$70-$149
Price range past year
Annual Return
-51.1%
Cumulative gain past year
| Period | ZTS Return | S&P 500 |
|---|---|---|
| 1m | -8.2% | +1.0% |
| 3m | -7.2% | +5.4% |
| 6m | -38.9% | +17.8% |
| 1y | -51.1% | +16.5% |
| ytd | -43.4% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ZTS Fundamental Analysis
Quarterly Revenue
$2.3B
2026-03
Revenue YoY Growth
+1.9%
YoY Comparison
Gross Margin
71.7%
Latest Quarter
Free Cash Flow
$2.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ZTS Overvalued?
PE
20.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 21x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant. The debt-to-equity ratio of 2.85 is elevated, and while interest expense of $62 million in Q1 2026 is manageable against $822 million in operating income, it consumes 7.5% of operating profits. Revenue growth has slowed to 1.89% year-over-year, and the company's reliance on companion animals (65% of revenue) exposes it to discretionary spending cuts. The trailing EPS of $0.048 is alarmingly low, and if forward EPS estimates of $9.06 are not met, the stock could face further multiple compression. Additionally, the payout ratio of 33.3% and dividend yield of 1.59% may be at risk if earnings decline. Market and competitive risks are intensifying. The stock's beta of 0.729 suggests lower volatility, but its 51.5% one-year decline shows it is not immune to sector-specific headwinds. The animal health industry is facing increased competition from generic alternatives and newer entrants, and Zoetis' key segments are sliding according to analyst reports. The relative strength versus the S&P 500 is -66.5% over one year, indicating a massive loss of investor confidence. If the broader market rotates away from healthcare or if interest rates remain elevated, the stock could continue to underperform. The worst-case scenario involves a continued decline in companion-animal spending, competitive share losses, and a miss on 2026 earnings guidance. In this scenario, the stock could retest its 52-week low of $71.00 (only 0.6% below current levels) and potentially fall to the analyst low target of $80.00 — wait, that's above current price. Actually, the 52-week low is $71.00, and the stock is at $71.40, so downside to the low is minimal. However, if the low is broken, the next support could be significantly lower, perhaps $60 or below, implying a 16% further decline. The max drawdown of -54.45% from the high of $148.79 illustrates the potential severity.
FAQ
The key risks include financial, competitive, macro, and company-specific factors. Financially, the debt-to-equity ratio of 2.85 is high, and the trailing EPS of $0.048 is weak, raising concerns about earnings quality. Competitively, the company faces pressure in key segments, with analysts questioning its growth pathway. Macro risks include a slowdown in pet spending due to economic uncertainty, which could disproportionately affect the companion-animal segment (65% of revenue). Company-specific risks include potential product failures or pipeline disappointments. Ranked by severity, the competitive and growth risks are most immediate, followed by financial leverage and macro sensitivity.
The 12-month forecast includes three scenarios: a bull case with 25% probability targeting $96-$155, a base case with 50% probability targeting $80-$96, and a bear case with 25% probability targeting $60-$71. The base case is most likely, assuming revenue growth of 2-4% and EPS of $9.06. The key assumption is that the companion-animal spending slowdown is cyclical, not structural. If growth accelerates, the stock could reach the bull case; if it deteriorates, the bear case could unfold. The average analyst target of $96 aligns with the base case, suggesting moderate upside from current levels.
ZTS appears undervalued on forward earnings but overvalued on other metrics. The forward PE of 10.93x is well below the trailing PE of 20.87x and the broader healthcare sector average, suggesting the market expects earnings to grow significantly. However, the price-to-book ratio of 16.75 and price-to-sales ratio of 5.89 are elevated, indicating that the stock is not cheap on an asset or revenue basis. The EV/EBITDA of 15.48 is also above the sector median. The market is pricing in a recovery in earnings, but if growth fails to materialize, the stock could remain under pressure. Relative to its own history, the forward PE is near multi-year lows, which could signal a value opportunity.
From a risk/reward perspective, ZTS presents a compelling but high-risk opportunity. The stock trades at $71.40, just above its 52-week low of $71.00, while the average analyst target is $96.00, implying 34.5% upside. The forward PE of 10.93x is low, but the trailing PE of 20.87x and PEG of 2.04 suggest the market is skeptical of earnings growth. The biggest downside risk is a break below $71, which could lead to a decline toward $60. For risk-tolerant investors with a long-term horizon, the stock could be a good buy on stabilization, but for those seeking near-term gains, the momentum remains negative.
ZTS is more suitable for long-term investment than short-term trading. The stock's beta of 0.729 indicates lower volatility, but its 51.5% one-year decline shows it can experience significant drawdowns. The dividend yield of 1.59% and payout ratio of 33.3% provide some income, but the primary appeal is capital appreciation if the company can reaccelerate growth. Earnings visibility is currently low due to competitive pressures, making short-term trading risky. A minimum holding period of 2-3 years is suggested to allow for a potential turnaround. Short-term traders might find opportunities around earnings, but the overall trend remains negative.